Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Only stories explicitly associated with this stock are shown.
The Riyadh Global Medical Biotechnology Summit 2026 concluded successfully with over 15,000 visitors from 57 countries and more than 40 agreements worth SAR 5.5 billion (USD 1.33 billion), significantly exceeding the 2024 edition's USD 100 million. The summit advanced Saudi Arabia's National Biotechnology Strategy through partnerships in vaccine manufacturing, genomics research, clinical trials, and workforce development with international organizations.
The Federal Reserve raised interest rates as anticipated and reported modestly higher inflation expectations. Despite the rate hike, the Fed raised its GDP growth outlook and characterized the labor market as solid, suggesting economic resilience.
The global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
TMO is currently shown at $648.43 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
A quantitative forecast is not currently available for TMO.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
There is not yet enough mature evaluation data on this page to claim a verified accuracy rate.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.